SAN DIEGO--(BUSINESS WIRE)--Rejuvenate Bio, today announced new preclinical efficacy data for RJB-0402, a gene therapy targeting key disease-mediating pathways. RJB-0402 demonstrated efficacy in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results